USGIU
SUPN icon

U.S. Global Investors (USGI)’s Supernus Pharmaceuticals SUPN Stock Holding History

U.S. Global Investors (USGI)’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-29,514
Closed -$701K – 191
2020
Q2 		$701K Buy
29,514
+3,700
+14% +$81.7K 0.07% 70
2020
Q1 		$464K Sell
25,814
-9,686
-27% -$204K 0.12% 77
2019
Q4 		$842K Buy
+35,500
New +$862K 0.38% 74
2018
Q1 		– Sell
-31,400
Closed -$1.25M – 133
2017
Q4 		$1.25M Sell
31,400
-600
-2% -$23.7K 0.57% 42
2017
Q3 		$1.28M Sell
32,000
-12,409
-28% -$537K 0.38% 56
2017
Q2 		$1.91M Buy
+44,409
New +$1.58M 0.66% 36

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

U.S. Global Investors (USGI)'s SUPN Position: Q3 2020 in Review

U.S. Global Investors (USGI) sold out of Supernus Pharmaceuticals (SUPN) in Q3 2020, closing a stake of 29,514 shares — an estimated $701K sold.

U.S. Global Investors (USGI) first reported a position in SUPN in Q2 2017 and held it in 6 quarters. The position peaked at $1.91M in Q2 2017. 209 funds tracked by Wall St. Rank hold SUPN as of Q3 2020.

  • U.S. Global Investors (USGI) reported no remaining Supernus Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • U.S. Global Investors (USGI) sold 29,514 Supernus Pharmaceuticals shares in Q3 2020, an estimated $701K.
  • U.S. Global Investors (USGI) first reported a position in Supernus Pharmaceuticals in Q2 2017 and held it in 6 quarters.
  • U.S. Global Investors (USGI)'s Supernus Pharmaceuticals position peaked at $1.91M in Q2 2017.
  • 209 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2020.

Based on U.S. Global Investors (USGI)'s 13F filing for Q3 2020, filed 13 Nov 2020.